The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignanciesL. Kerrie, Jeffery L. Kutok|PLoS ONE|2018Cited by 29